戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                        Estrogens demonstrate vasoprotective activity in many experimental models.
2 rahydrobiopterin (BH4) is a major endogenous vasoprotective agent that improves endothelial function
3 ilability, and employing neuroprotective and vasoprotective agents.
4 ed octapeptides suggesting that their potent vasoprotective and anti-inflammatory activity is not nit
5   These results suggest an interplay between vasoprotective and pro-inflammatory endothelial molecule
6 etin have shown antioxidant, cytoprotective, vasoprotective, antiproliferative and antiinflammatory p
7                  Hydrogen sulphide (H2 S) is vasoprotective, attenuates inflammation and modulates bl
8 anding of the physiology and pharmacology of vasoprotective axis in bone marrow-derived progenitor ce
9 ects were associated with an increase in the vasoprotective axis of the lung renin-angiotensin system
10  enzyme (ACE)-2 is the primary enzyme of the vasoprotective axis of the renin angiotensin system that
11                                Oestradiol is vasoprotective because it has direct and indirect effect
12  sexes, whether (1) exogenous estrogen has a vasoprotective effect in injured carotid arteries, (2) p
13              These results indicate that the vasoprotective effect of E2 in the balloon-injured rat c
14  antagonist, to test the hypothesis that the vasoprotective effect of E2 in the rat carotid injury mo
15 ably by blocking the production and thus the vasoprotective effect of endogenous estrogen.
16 medroxyprogesterone acetate, MPA) blocks the vasoprotective effect of estrogen, and (3) any observed
17                       The mechanisms of this vasoprotective effect of female sex are incompletely und
18                                          The vasoprotective effect of hormone replacement therapy may
19                                         This vasoprotective effect was independent of enhanced circul
20 lling into question the ER dependency of the vasoprotective effect.
21 gesting that 17beta-estradiol may also exert vasoprotective effects in cerebral blood vessels via sti
22           These results demonstrate that the vasoprotective effects of E(2) after ligation vascular i
23 se, likely because of its attenuation of the vasoprotective effects of endothelial nitric oxide synth
24                                          The vasoprotective effects of estrogen are age-dependent and
25                                          The vasoprotective effects of estrogen are mediated by estro
26      Future studies designed to preserve the vasoprotective effects of estrogen in older women are ne
27 tions of ER and is essential for many of the vasoprotective effects of estrogen.
28 eas addition of MPA to estradiol blocked the vasoprotective effects of estrogen.
29 t another potential mechanism underlying the vasoprotective effects of estrogens but also that the es
30  but not intact females are resistant to the vasoprotective effects of exogenous estrogen, despite at
31                                          The vasoprotective effects of nitrite were counteracted by i
32  of SOCS3 abolished the antiinflammatory and vasoprotective effects of RORalpha deficiency in vitro a
33                                          The vasoprotective effects of statins in heart transplant re
34  that SRC-3 largely facilitates ER-dependent vasoprotective effects under conditions of vascular trau
35                                      In vivo vasoprotective effects were determined using: (1) a carr
36                       Because oestradiol has vasoprotective effects, the menopause-associated drop in
37 f nitric oxide, may exert vasomodulatory and vasoprotective effects.
38 eptor that primarily underlies CNP-dependent vasoprotective functions and developed small-molecule NP
39 d preservation solution on the expression of vasoprotective genes, and on endothelial activation and
40                                  Estrogen is vasoprotective in animal models of vascular injury, yet
41 ous studies have shown that estrogen (E2) is vasoprotective in multiple animal models of vascular inj
42 w therapy for patients with PAH who lack the vasoprotective LRP1 in vascular SMC.
43                                  This innate vasoprotective mechanism is impaired in certain chronic
44 lls isolated from young women but that these vasoprotective mechanisms are lost in women who are aged
45 te that HO-1 represents an important in vivo vasoprotective mediator that is capable of attenuating t
46 , 9.0+/-2.4%), and the rates of use of other vasoprotective medications were low (e.g., 30% of partic
47                     Estrogen is an important vasoprotective molecule that causes the rapid dilation o
48        Endothelial thrombomodulin is a major vasoprotective molecule.
49                 Prostacyclin is an important vasoprotective molecule.
50 othelial glycocalyx (eGC) is recognized as a vasoprotective nanobarrier and responsive hub.
51 utral sphingomyelinase) elicits formation of vasoprotective nitric oxide (NO).
52 xygen and nitrogen free radicals rather than vasoprotective nitric oxide for unclear reasons.
53 ment blocked the decay of KLF2, sustaining a vasoprotective phenotype, and preventing endothelial act
54 nale to evaluate the beneficial effects of a vasoprotective preservation solution on human liver proc
55                   Expression of KLF2 and its vasoprotective programs decrease in HEC incubated under
56                   Expression of KLF2 and its vasoprotective programs was determined in (i) hepatic en
57 cold storage conditions disrupts endothelial vasoprotective programs, and that this consequence of st
58 harmacologic agents that restore endothelial vasoprotective programs, by upregulating KLF2, may repre
59  storage solution, maintained KLF2-dependent vasoprotective programs, prevented liver damage, inflamm
60                  This study highlights BNP's vasoprotective propensity, bringing to light a possible
61 is a peptide molecule with anti-fibrotic and vasoprotective properties that binds to relaxin family p
62 sidering the fact that nitric oxide exhibits vasoprotective properties, we examined the effects of ni
63 estoring the balance between the classic and vasoprotective renin angiotensin system.
64           Platelets are best known for their vasoprotective responses to injury and inflammation.
65                            Given the central vasoprotective role of endothelium, these findings could
66                                 Such a novel vasoprotective role of PGRN may contribute to brain dysf
67 rogenitor cells (EPCs) enhance production of vasoprotective substances in cerebral arteries.
68  factor Kruppel-like factor 2 (KLF2) and its vasoprotective target genes were assessed during cold st
69 naling is altered in older women, converting vasoprotective to vasotoxic effects.
70  due to a reduction in the expression of the vasoprotective transcription factor Kruppel-like Factor
71   The expression of endothelial KLF2 and its vasoprotective transcriptional targets were rapidly lost
72  is exposed to various flow patterns such as vasoprotective unidirectional laminar shear stress (LSS)